miR-29b-3p inhibits post-infarct cardiac fibrosis by targeting FOS

Area of Science:

• Cardiovascular Biology
• Molecular Cardiology
• Fibrosis Research

Background:

• Cardiac fibrosis following myocardial infarction (MI) significantly impairs heart function.
• MicroRNAs (miRNAs) are increasingly recognized for their roles in cardiovascular diseases, including fibrosis.
• This study focuses on the specific role and mechanism of miR-29b-3p in post-MI cardiac fibrosis.

Purpose of the Study:

• To investigate the function of miR-29b-3p in cardiac fibrosis.
• To elucidate the underlying molecular mechanism of miR-29b-3p in regulating cardiac fibroblast behavior.
• To determine the therapeutic potential of miR-29b-3p in mitigating cardiac fibrosis.

Main Methods:

• Quantitative real-time PCR (qRT-PCR) to measure miR-29b-3p expression.
• Cell Counting Kit-8 (CCK-8) and Trans-well assays to assess fibroblast proliferation and migration.
• Western blot to analyze protein expression (α-SMA, collagen I, III, MMP2, MMP9).
• Bioinformatics, luciferase, and RNA immunoprecipitation (RIP) assays to identify miR-29b-3p targets.

Main Results:

• Transforming growth factor-beta 1 (TGF-β1) suppressed miR-29b-3p expression in cardiac fibroblasts (CFs) in a dose-dependent manner.
• miR-29b-3p attenuated TGF-β1-induced proliferation, migration, and differentiation of CFs.
• FOS was identified as a direct target of miR-29b-3p; elevated FOS expression counteracted miR-29b-3p's inhibitory effects.

Conclusions:

• miR-29b-3p counteracts TGF-β1-induced pro-fibrotic effects by targeting FOS.
• This mechanism highlights miR-29b-3p as a potential therapeutic target for cardiac fibrosis post-MI.